Edwards to market PLC's TMR heart laser in US:
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences is to have exclusive rights to sell PLC Medical Systems' next generation CO2 TMR heart laser in the US under a multi-year agreement. The product is awaiting FDA approval. Edwards will also take a $4 million equity investment in Franklin, Massachusetts-based PLC and will receive warrants to buy three million shares. "We believe Edwards' substantial sales and marketing resources combined with PLC's technological leadership will establish CO2 TMR as the standard of care in laser-powered heart revascularisation," said Mark Tauscher, PLC's CEO.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.